- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01990456
Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study (SOLVE ARDS)
Due to lack of studies on mechanical ventilation strategies in patients with severe Acute Respiratory Distress Syndrome (ARDS) supported with Veno-Venous Extra-Corporeal Membrane Oxygenation (VV ECMO), ventilator settings in this patient population are set arbitrarily.
In this two-phases prospective, interventional, pilot study we hope to gain physiologically relevant data on two aspects of mechanical ventilation in patients with severe ARDS supported with VV ECMO: (1) the use of tidal ventilation and (2) the level of Positive End-Expiratory Pressure (PEEP).
PHASE 1: impact of tidal ventilation on VILI (10 patients) We hypothesized that a CPAP strategy that minimizes end-tidal pulmonary stress and strain mitigates VILI compared to the current mechanical ventilation practice that employs tidal ventilation in patients with severe ARDS on ECMO.
In this first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
- PHASE 2: impact of PEEP on VILI (10 patients) We also hypothesized that adjusting PEEP to maximize respiratory system compliance reduces VILI in patients with severe ARDS on ECMO.
In the second phase we will therefore gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
Because ARDS patients supported with VV ECMO can be hemodynamically unstable, the use of imaging techniques that require transport, such as computed tomography, is limited. Therefore, bedside imaging techniques, such as pleural and lung ultrasound (PLUS) and focused bedside cardiac ultrasonography, are important tools for clinicians who care for these patients. This study will allow us to learn whether these techniques are feasible and valid in this patient population.
Furthermore, the knowledge gained from this study will allow us to assess the rationale and feasibility of performing a similar larger, randomized study in the future.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Recruiting
- Medical Surgical ICU - Toronto General Hospital
-
Contact:
- Eddy Fan, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe ARDS (Berlin Definition)
- VV ECMO < 72 hours
- Endotracheal intubation or tracheostomy
Exclusion Criteria:
- Thoracic surgery/lung transplantation during the current hospitalization
- Contraindications to a RM (MAP < 60 mmHg despite administration of fluids and vasopressors; Active air leak through a thoracostomy tube; Pneumothorax, or subcutaneous or mediastinal emphysema, (if chest tube has not been inserted))
- Contraindications to TEE
- Age < 16 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: PHASE 1: impact of tidal ventilation on VILI
In the first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
|
PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
|
|
EXPERIMENTAL: PHASE 2: impact of PEEP on VILI
In the second phase we will gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP).
We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
|
PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ventilator-Induced Lung Injury (VILI) in patients with ARDS on ECMO ventilated with different strategies (tidal ventilation, CPAP, ZEEP), as measured by Serum Cytokines
Time Frame: 1 hour after initiation of each experimental ventilation strategy
|
1 hour after initiation of each experimental ventilation strategy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of a CPAP strategy (PEEP set at best compliance and at ZEEP) in patients with severe ARDS on ECMO, as measured by transesophageal echocardiography (TEE)
Time Frame: 30 minutes after initiation of experimental CPAP/ZEEP strategy
|
Quantification of RV function:
|
30 minutes after initiation of experimental CPAP/ZEEP strategy
|
|
Feasibility and validity of focused cardiac ultrasound, as compared to TEE as gold standard, in the assessment of RV function in patients with ARDS on ECMO
Time Frame: 30 minutes after initiation of experimental CPAP/ZEEP strategy
|
Quantification of RV function:
|
30 minutes after initiation of experimental CPAP/ZEEP strategy
|
|
Feasibility of lung ultrasound in patients with severe ARDS on ECMO
Time Frame: 30 minutes after initiation of experimental CPAP/ZEEP strategy
|
Lung Ultrasound Score
|
30 minutes after initiation of experimental CPAP/ZEEP strategy
|
|
Feasibility (patient recruitment, protocol adherence, physiologic tolerability)
Time Frame: At overall study completion (i.e., 24 months from study start or after enrolment of last patient)
|
This outcome will be assessed by:
|
At overall study completion (i.e., 24 months from study start or after enrolment of last patient)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eddy Fan, MD, PhD, University Health Network, University of Toronto
- Principal Investigator: Niall D. Ferguson, MD, MSc, University Health Network, University of Toronto
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SOLVE ARDS_01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome, Adult
-
Wolfson Medical CenterUnknown
-
Centre Hospitalier Universitaire de NiceCompletedRespiratory Distress Syndrome,AdultFrance
-
Abbott NutritionTerminatedAcute Lung Injury | Respiratory Distress Syndrome,AdultRussian Federation
-
GlaxoSmithKlineTerminatedLung Injury, Acute and Respiratory Distress Syndrome, AdultUnited Kingdom
-
Amazon UniversitySanta Casa de Misericórdia do ParáCompletedSepsis | HELLP Syndrome | Postpartum Period | Respiratory Distress Syndrome,Adult
-
Michael A. MatthayThe University of Texas Health Science Center, Houston; United States Department... and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Dompé Farmaceutici S.p.ACompletedAcute Respiratory Distress Syndrome, AdultUnited States, Italy, Germany
-
Implicit BioscienceUniversity of WashingtonRecruitingAcute Respiratory Distress Syndrome | Acute Lung Injury | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Adult Respiratory Distress SyndromeUnited States
-
Faron Pharmaceuticals LtdSeventh Framework ProgrammeTerminatedRespiratory Distress Syndrome, AdultSpain, United Kingdom, France, Italy, Finland, Czechia, Belgium, Germany
-
Karolinska University HospitalKarolinska InstitutetUnknownAcute Respiratory Distress Syndrome, AdultSweden
Clinical Trials on PHASE 1: impact of tidal ventilation on VILI
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Rudolf KnippActive, not recruiting
-
South Valley UniversityNot yet recruitingVentilator-Induced Diaphragmatic Dysfunction
-
Centre Hospitalier Intercommunal Robert BallangerRecruiting
-
Jagiellonian UniversityCompletedSubclinical hypothyroïdism | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries | Hypothalamic-Pituitary-Gonadal Axis DysfunctionPoland
-
Memorial Sloan Kettering Cancer CenterAlbert Einstein College of Medicine; National Institutes of Health (NIH); State... and other collaboratorsCompletedColon CancerUnited States
-
Postgraduate Institute of Medical Education and...TerminatedAcute Respiratory Distress Syndrome (ARDS)India
-
Universidad Nacional de CórdobaRecruiting
-
Çanakkale Onsekiz Mart UniversityActive, not recruitingLumbar Disc Herniation | Surgical Site InfectionsTurkey (Türkiye)
-
MGC Pharmaceuticals d.o.oActive, not recruitingCovid19 | Corona Virus Infection | SARS-CoV InfectionIsrael